Want to see AVTX full AI Analyst Report?
AVTX Stock Chart & Stats
$18.44
$0.68(3.83%)
At close: 4:00 PM EDT
$18.44
$0.68(3.83%)
Day’s Range― - ―
52-Week Range$8.41 - $24.27
Previous CloseN/A
Volume800.24K
Average Volume (3M)1.65M
Market Cap
$1.07B
Enterprise Value$407.68
Total Cash (Recent Filing)$400.28M
Total Debt (Recent Filing)$242.00K
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Nov 05, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.74
Shares Outstanding53,629,990
10 Day Avg. Volume849,341
30 Day Avg. Volume1,653,958
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.93
Price to Sales (P/S)4125.96
P/FCF Ratio-4.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$41.80Price Target Upside126.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress (abdakibart)Positive Phase 2 topline and explicit intent to move abdakibart into a registrational Phase 3 materially de-risks the lead program's clinical pathway. Success or clear Phase 3 design reduces regulatory and development uncertainty and anchors the company's strategic focus over the next 2-6 months.
Pipeline Expansion (AVTX-010)Introducing AVTX-010 as a long-acting follow-on to abdakibart strengthens the company’s IL-1β franchise, potentially creating product differentiation via less frequent dosing. A broadened pipeline increases optionality, IP potential and long-term competitive positioning in inflammatory diseases.
Improved Funding RunwayA sizeable $~405M equity and warrant financing meaningfully extends cash runway to fund pivotal Phase 3 and IND-enabling work, reducing near-term solvency risk. Combined with low current leverage, this funding supports execution of clinical milestones over the medium term.
Bears Say
Minimal And Declining RevenueAvalo remains a pre-commercial biotech with revenues that have declined materially; the TTM revenue base is minimal. Lack of recurring product sales means value is fully dependent on clinical success and external financing, constraining reinvestment and making operations sensitive to trial outcomes.
Persistent Cash BurnSustained negative operating and free cash flows indicate high cash burn inherent to clinical development. Continued outflows necessitate future financings unless costs are cut or revenue emerges, increasing execution risk and potentially delaying development timelines if funding availability tightens.
Dilution And Governance ShiftsStructural financing and governance moves—ownership limit expansions, new convertible preferred series, and enhanced executive change-of-control protections—can increase dilution risk and alter incentive alignment. Such shifts may raise long-term shareholder dilution and complicate capital structure during future financings.
Avalo Therapeutics News
AVTX FAQ
What was Avalo Therapeutics, Inc.’s price range in the past 12 months?
Avalo Therapeutics, Inc. lowest stock price was $8.41 and its highest was $24.27 in the past 12 months.
What is Avalo Therapeutics, Inc.’s market cap?
Avalo Therapeutics, Inc.’s market cap is $1.07B.
When is Avalo Therapeutics, Inc.’s upcoming earnings report date?
Avalo Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 78 days.
How were Avalo Therapeutics, Inc.’s earnings last quarter?
Avalo Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.583 by -$0.247.
Is Avalo Therapeutics, Inc. overvalued?
According to Wall Street analysts Avalo Therapeutics, Inc.’s price is currently Undervalued.
Does Avalo Therapeutics, Inc. pay dividends?
Avalo Therapeutics, Inc. does not currently pay dividends.
What is Avalo Therapeutics, Inc.’s EPS estimate?
Avalo Therapeutics, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Avalo Therapeutics, Inc. have?
Avalo Therapeutics, Inc. has 53,629,990 shares outstanding.
What happened to Avalo Therapeutics, Inc.’s price movement after its last earnings report?
Avalo Therapeutics, Inc. reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.583. Following the earnings report the stock price went down -0.743%.
Which hedge fund is a major shareholder of Avalo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AVTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avalo Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.80 (126.68% Upside)
$41.80 (126.68% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 894.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $748.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
178.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
287.72%
Trailing 12-Months
Company Description
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
AVTX Stock 12 Month Forecast
Average Price Target
$41.80
▲(126.68% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Fractyl Health, Inc.
―
Ownership Overview
0.70% Insiders
8.57% Mutual Funds
71.31% Other Institutional Investors
6.57% Public Companies and
Individual Investors